BACKGROUND: We report the first-in-human safety and immunogenicity assessment of a prototype Ad26 vector-based human immunodeficiency virus (HIV) vaccine in humans. METHODS:Sixty Ad26-seronegative, healthy, HIV-uninfected subjects were enrolled in a randomized, double-blinded, placebo-controlled, dose-escalation phase 1 study. Five groups of 12 subjects received 10(9)-10(11) vp of the Ad26-EnvA vaccine (N = 10/group) or placebo (N = 2/group) at weeks 0 and 24 or weeks 0, 4, and 24. Safety and immunogenicity were assessed. RESULTS:Self-limited reactogenicity was observed after the initial immunization at the highest (10(11) vp) dose. No product-related SAEs were observed. All subjects who received the Ad26-EnvA vaccine developed Ad26 NAb titers, EnvA-specific enzyme-linked immunosorbent assays (ELISA) titers, and EnvA-specific enzyme-linked immunospot assays (ELISPOT) responses. These responses persisted at week 52. At week 28 in the 10(9), 10(10), 10(11) vp 3-dose and the 10(10) and 5 × 10(10) vp 2-dose groups, geometric mean EnvA ELISA titers were 6113, 12 470, 8545, 3470, and 9655 and mean EnvA ELISPOT responses were 397, 178, 736, 196, and 1311 SFC/10(6) peripheral blood mononuclear cells, respectively. CONCLUSION: This Ad26 vectored vaccine was generally safe and immunogenic at all doses tested. Reactogenicity was minimal with doses of 5 × 10(10) vp or less. Ad26 is a promising new vaccine vector for HIV-1. CLINICAL TRIALS REGISTRATION: NCT00618605.
RCT Entities:
BACKGROUND: We report the first-in-human safety and immunogenicity assessment of a prototype Ad26 vector-based human immunodeficiency virus (HIV) vaccine in humans. METHODS: Sixty Ad26-seronegative, healthy, HIV-uninfected subjects were enrolled in a randomized, double-blinded, placebo-controlled, dose-escalation phase 1 study. Five groups of 12 subjects received 10(9)-10(11) vp of the Ad26-EnvA vaccine (N = 10/group) or placebo (N = 2/group) at weeks 0 and 24 or weeks 0, 4, and 24. Safety and immunogenicity were assessed. RESULTS: Self-limited reactogenicity was observed after the initial immunization at the highest (10(11) vp) dose. No product-related SAEs were observed. All subjects who received the Ad26-EnvA vaccine developed Ad26 NAb titers, EnvA-specific enzyme-linked immunosorbent assays (ELISA) titers, and EnvA-specific enzyme-linked immunospot assays (ELISPOT) responses. These responses persisted at week 52. At week 28 in the 10(9), 10(10), 10(11) vp 3-dose and the 10(10) and 5 × 10(10) vp 2-dose groups, geometric mean EnvA ELISA titers were 6113, 12 470, 8545, 3470, and 9655 and mean EnvA ELISPOT responses were 397, 178, 736, 196, and 1311 SFC/10(6) peripheral blood mononuclear cells, respectively. CONCLUSION: This Ad26 vectored vaccine was generally safe and immunogenic at all doses tested. Reactogenicity was minimal with doses of 5 × 10(10) vp or less. Ad26 is a promising new vaccine vector for HIV-1. CLINICAL TRIALS REGISTRATION: NCT00618605.
Authors: Karin Loré; William C Adams; Menzo J E Havenga; Melissa L Precopio; Lennart Holterman; Jaap Goudsmit; Richard A Koup Journal: J Immunol Date: 2007-08-01 Impact factor: 5.422
Authors: Neil M Flynn; Donald N Forthal; Clayton D Harro; Franklyn N Judson; Kenneth H Mayer; Michael F Para Journal: J Infect Dis Date: 2005-01-27 Impact factor: 5.226
Authors: Andrew T Catanzaro; Richard A Koup; Mario Roederer; Robert T Bailer; Mary E Enama; Zoe Moodie; Lin Gu; Julie E Martin; Laura Novik; Bimal K Chakrabarti; Bryan T Butman; Jason G D Gall; C Richter King; Charla A Andrews; Rebecca Sheets; Phillip L Gomez; John R Mascola; Gary J Nabel; Barney S Graham Journal: J Infect Dis Date: 2006-11-08 Impact factor: 5.226
Authors: Peter Abbink; Angelique A C Lemckert; Bonnie A Ewald; Diana M Lynch; Matthew Denholtz; Shirley Smits; Lennart Holterman; Irma Damen; Ronald Vogels; Anna R Thorner; Kara L O'Brien; Angela Carville; Keith G Mansfield; Jaap Goudsmit; Menzo J E Havenga; Dan H Barouch Journal: J Virol Date: 2007-02-28 Impact factor: 5.103
Authors: Jinyan Liu; Bonnie A Ewald; Diana M Lynch; Matthew Denholtz; Peter Abbink; Angelique A C Lemckert; Angela Carville; Keith G Mansfield; Menzo J Havenga; Jaap Goudsmit; Dan H Barouch Journal: J Virol Date: 2008-03-12 Impact factor: 5.103
Authors: Frances H Priddy; Deborah Brown; James Kublin; Kathleen Monahan; David P Wright; Jacob Lalezari; Steven Santiago; Michael Marmor; Michelle Lally; Richard M Novak; Stephen J Brown; Priya Kulkarni; Sheri A Dubey; Lisa S Kierstead; Danilo R Casimiro; Robin Mogg; Mark J DiNubile; John W Shiver; Randi Y Leavitt; Michael N Robertson; Devan V Mehrotra; Erin Quirk Journal: Clin Infect Dis Date: 2008-06-01 Impact factor: 9.079
Authors: Dan H Barouch; Jinyan Liu; Lauren Peter; Peter Abbink; M Justin Iampietro; Ann Cheung; Galit Alter; Amy Chung; Anne-Sophie Dugast; Nicole Frahm; M Juliana McElrath; Holger Wenschuh; Ulf Reimer; Michael S Seaman; Maria G Pau; Mo Weijtens; Jaap Goudsmit; Stephen R Walsh; Raphael Dolin; Lindsey R Baden Journal: J Infect Dis Date: 2012-11-02 Impact factor: 5.226
Authors: M Juliana McElrath; Stephen C De Rosa; Zoe Moodie; Sheri Dubey; Lisa Kierstead; Holly Janes; Olivier D Defawe; Donald K Carter; John Hural; Rama Akondy; Susan P Buchbinder; Michael N Robertson; Devan V Mehrotra; Steven G Self; Lawrence Corey; John W Shiver; Danilo R Casimiro Journal: Lancet Date: 2008-11-13 Impact factor: 79.321
Authors: Susan P Buchbinder; Devan V Mehrotra; Ann Duerr; Daniel W Fitzgerald; Robin Mogg; David Li; Peter B Gilbert; Javier R Lama; Michael Marmor; Carlos Del Rio; M Juliana McElrath; Danilo R Casimiro; Keith M Gottesdiener; Jeffrey A Chodakewitz; Lawrence Corey; Michael N Robertson Journal: Lancet Date: 2008-11-13 Impact factor: 79.321
Authors: Ashrafali Mohamed Ismail; Xiaohong Zhou; David W Dyer; Donald Seto; Jaya Rajaiya; James Chodosh Journal: FEBS Lett Date: 2019-12-11 Impact factor: 4.124
Authors: Leslie van der Fits; Renske Bolder; Marjolein Heemskerk-van der Meer; Joke Drijver; Yolinda van Polanen; Jan Serroyen; Johannes P M Langedijk; Hanneke Schuitemaker; Eirikur Saeland; Roland Zahn Journal: NPJ Vaccines Date: 2020-06-12 Impact factor: 7.344
Authors: Nicholas M Provine; Rafael A Larocca; Pablo Penaloza-MacMaster; Erica N Borducchi; Anna McNally; Lily R Parenteau; David R Kaufman; Dan H Barouch Journal: J Immunol Date: 2014-04-28 Impact factor: 5.422
Authors: Nicholas M Provine; Rafael A Larocca; Malika Aid; Pablo Penaloza-MacMaster; Alexander Badamchi-Zadeh; Erica N Borducchi; Kathleen B Yates; Peter Abbink; Marinela Kirilova; David Ng'ang'a; Jonathan Bramson; W Nicholas Haining; Dan H Barouch Journal: J Immunol Date: 2016-07-22 Impact factor: 5.422